DDAH II Antibody (3E3): sc-293229

DDAH II Antibody (3E3) is a mouse monoclonal IgG2b kappa light chain antibody that detects DDAH II protein of human origin by western blotting (WB), immunoprecipitation (IP), and enzyme-linked immunosorbent assay (ELISA). Anti-DDAH II antibody (3E3) is available as the non-conjugated format. DDAH II, a member of the dimethylarginine dimethylaminohydrolase family, plays a crucial role in regulating nitric oxide production by hydrolyzing the endogenous inhibitors dimethylarginine (ADMA) and monomethyl arginine (MMA). DDAH II modulates vascular function and blood flow, as impaired DDAH activity leads to ADMA accumulation, which can result in reduced nitric oxide synthesis and subsequent cardiovascular complications. DDAH II is predominantly expressed in endothelial cells, where DDAH II facilitates the induction of nitric oxide synthesis in response to all-trans-retinoic acid (atRA). This regulation is vital for maintaining vascular homeostasis and preventing endothelial dysfunction. DDAH proteins are highly expressed in various tissues, including the colon, kidney, stomach, and liver, underscoring their significance in multiple physiological processes.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

DDAH II Antibody (3E3) References:

1. Dimethylarginine dimethylaminohydrolase (DDAH) as a nerve-injury-associated molecule: mRNA localization in the rat brain and its coincident up-regulation with neuronal NO synthase (nNOS) in axotomized motoneurons.  |  Nakagomi, S., et al. 1999. Eur J Neurosci. 11: 2160-6. PMID: 10336684
2. Structural and functional characterization of the Zn(II) site in dimethylargininase-1 (DDAH-1) from bovine brain. Zn(II) release activates DDAH-1.  |  Knipp, M., et al. 2001. J Biol Chem. 276: 40449-56. PMID: 11546769
3. all-trans-Retinoic acid increases nitric oxide synthesis by endothelial cells: a role for the induction of dimethylarginine dimethylaminohydrolase.  |  Achan, V., et al. 2002. Circ Res. 90: 764-9. PMID: 11964368
4. Impaired nitric oxide synthase pathway in diabetes mellitus: role of asymmetric dimethylarginine and dimethylarginine dimethylaminohydrolase.  |  Lin, KY., et al. 2002. Circulation. 106: 987-92. PMID: 12186805
5. S-nitrosylation of dimethylarginine dimethylaminohydrolase regulates enzyme activity: further interactions between nitric oxide synthase and dimethylarginine dimethylaminohydrolase.  |  Leiper, J., et al. 2002. Proc Natl Acad Sci U S A. 99: 13527-32. PMID: 12370443
6. Zn(II)-free dimethylargininase-1 (DDAH-1) is inhibited upon specific Cys-S-nitrosylation.  |  Knipp, M., et al. 2003. J Biol Chem. 278: 3410-6. PMID: 12441345
7. DDAH2 mRNA expression is inversely associated with some cardiovascular risk-related features in healthy young adults.  |  Puchau, B., et al. 2009. Dis Markers. 27: 37-44. PMID: 19822957
8. Association of the DDAH2 gene polymorphism with type 2 diabetes and hypertension.  |  Seo, HA., et al. 2012. Diabetes Res Clin Pract. 98: 125-31. PMID: 22579530
9. Protective role of DDAH2 (rs805304) gene polymorphism in patients with myocardial infarction.  |  Pérez-Hernández, N., et al. 2014. Exp Mol Pathol. 97: 393-8. PMID: 25236572
10. DDAH1 and DDAH2 polymorphisms associate with asymmetrical dimethylarginine plasma levels in erectile dysfunction patients but not in healthy controls.  |  Brites-Anselmi, G., et al. 2019. Nitric Oxide. 92: 11-17. PMID: 31394201
11. Insights of upregulating of DDAH2 expression by pharmacological action.  |  Zhang, D., et al. 2022. Int J Cardiol. 364: 103. PMID: 35660556
12. Assessment of DDAH1 and DDAH2 Contributions to Psychiatric Disorders via In Silico Methods.  |  Kozlova, AA., et al. 2022. Int J Mol Sci. 23: PMID: 36233204